Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Team Develops Novel Antibody-Drug Conjugate Delivery Methodology

Page View:

    This is a good news for people suffering with cancer as they may soon face better therapy with the coming of a new drug delivery method.


    Researchers from the Florida campus of The Scripps Research Institute (TSRI) say they have developed a new drug delivery method that produces strong results in treating cancers in animal models, including some hard-to-treat solid and liquid tumors. The study (“Stable and Potent Selenomab-Drug Conjugates”), led by TSRI associate professor Christoph Rader, Ph.D., was published online ahead of print in Cell Chemical Biology.


Team Develops Novel Antibody-Drug Conjugate Delivery Methodology


    The new method involves antibody–drug conjugates (ADCs), which include some of the most promising next-generation antibody therapeutics for cancer. ADCs can deliver a cytotoxic payload in a way that is tumor selective. So far, three ADCs have been approved by the FDA, but neither attaches the drug to a defined site on the antibody.


    “We’ve been working on this technology for some time,” Dr. Rader said. “It’s based on the rarely used natural amino acid selenocysteine, which we insert into our antibodies. We refer to these engineered antibodies as selenomabs.


    “We now show for the first time that selenomab–drug conjugates, which are ADCs that utilize the unique reactivity of selenocysteine for drug attachment, are highly precise, stable, and potent compositions and promise broad utility for cancer therapy.”


    Along with its potency, Dr. Rader noted, the ADC’s stability is critical to its effectiveness. The researchers found that their new ADCs showed excellent stability in human blood in vitro and in circulating blood in animal models. Moreover, the new ADCs were highly effective against HER2 breast cancer, a particularly difficult cancer to treat, and against CD138 multiple myeloma. Importantly, the ADCs did not harm healthy cells and tissues.


    “The selenomab–drug conjugate significantly inhibited the growth of an aggressive breast cancer,” said TSRI research associate Xiuling Li, Ph.D., first author of the study. “Four of the five mice tested were tumor-free at the end of the experiment, a full 6 weeks after their last treatment.”


    The researchers plan to investigate similar ADCs going forward. Dr. Rader, along with TSRI professor Ben Shen, Ph.D., was recently awarded $3.3 million from the National Cancer Institute of the National Institutes of Health to test highly cytotoxic natural products discovered in the Shen lab using selenomabs as drug delivery vehicles.

Relevant newsRelevant news